PTH 1-34
Parathyroid Hormone Fragment 1-34 (Teriparatide)
The anabolic fragment of parathyroid hormone. FDA-approved (Forteo) for severe osteoporosis. The only approved anabolic bone-building treatment.
Mechanism of Action
PTH 1-34 binds to PTH1R receptors on osteoblasts, stimulating bone formation when administered intermittently (pulsatile). Continuous PTH elevation causes bone resorption; pulsatile dosing produces net bone gain.
Health Claims & Evidence
Anabolic bone building and fracture risk reduction
Reduces vertebral and non-vertebral fracture risk
Accelerates fracture healing
Short-Term Effects
Bone density increases measurable within months.
Long-Term Effects
Significant bone density gains and fracture risk reduction over 2-year course.
Side Effects
Nausea, dizziness, leg cramps, hypercalcemia. Osteosarcoma risk in animal studies (not confirmed in humans).
Contraindications
History of bone cancer, Paget's disease, prior radiation to skeleton. Maximum 2-year lifetime use.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Teriparatide and osteoporosis
Neer et al. · New England Journal of Medicine · 2001
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on PTH 1-34 and related peptides, and prepare an educational research summary.
Explore Research